The short version of lyophilisation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Susineridine (INNTooltip International Nonproprietary Name; developmental code name YZJ-4729) is an atypical μ-opioid receptor (MOR) agonist and opioid analgesic which is under development for the treatment of postoperative pain. It is given intravenously. The drug acts as a selective biased partial agonist of the MOR, with functional selectivity for activation of G protein signaling over β-arrestin2 recruitment. Its mechanism of action and pharmacological activity are said to be similar to those of oliceridine. However, in-vitro findings suggest that susineridine may have a greater degree of G protein bias than oliceridine. The drug produces analgesic effects in multiple animal models of pain and produces less respiratory depression than morphine or oliceridine. The pharmacokinetics of susineridine in humans have been studied. Susineridine was patented and first described in the scientific literature in 2023. It is under development by Shanghai Haiyan Pharmaceutical Technology in China. As of May 2025, the drug is in phase 3 clinical trials for postoperative pain.
Children with simple steatosis have a worse prognosis than adults, with significantly more of them progressing from MASFLD to MASH compared to adults. Indeed, 17-25% of children with MASLD develop MASH in general, and up to 83% for children with severe obesity (versus 29% for adults), further suggesting that hepatic fibrosis seems to follow a more aggressive clinical course in children compared to adults. Early diagnosis of MASLD in children may help prevent the development of liver disease during adulthood. This is challenging as most children with MASLD are asymptomatic, with only 42-59% showing abdominal pain. Other symptoms might be present, such as right upper quadrant pain or acanthosis nigricans, the latter of which is often present in children with MASH. An enlarged liver occurs in 30–40% of children with MASFLD. The AASLD recommends a diagnostic liver biopsy in children when the diagnosis is unclear or before starting a potentially hepatotoxic medical therapy. The EASL suggests using fibrosis tests such as elastography, acoustic radiation force impulse imaging, and serum biomarkers to reduce the number of biopsies. In follow-up, NICE guidelines recommend that healthcare providers offer children regular MASLD screening for advanced liver fibrosis every two years using the enhanced liver fibrosis (ELF) blood test. Several studies also suggest magnetic resonance elastography as an alternative to the less reliable ultrasonography.
=== Natural Resource Group === In 1975, the Natural Resources Group of W.R. Grace created the oil and gas contract drilling company of TRG Drilling Corporation. The new corporation started with three oil rigs were previously owned by Amini Oil and Magness Petroleum. In 1978, the Natural Resources Group announced that it will be combining the three oil companies owned by the company into Grace Petroleum Corporation. In 1982, Grace announced that it was creating Grace Drilling Company of Oklahoma which would consolidate what was at that time its six drilling contractors into one company. The units had previously operated as part of the TRG Drilling Corporation and had generated $253 in sales revenue in 1981. The consolidation, the company said, would make it the largest land drilling operations contractor in the Lower 48 with 116 wells.
Rémi Goulet (born 1997) is a Canadian film and television actor from Lavaltrie, Quebec, best known for his regular supporting role as Benji, the younger brother of protagonist Chuck, in the television series Pour toujours, plus un jour. He began his career as a child actor, with roles in the television series 30 vies and Tactik, and the film The Pee-Wee 3D: The Winter That Changed My Life (Les Pee-Wee 3d: L'hiver qui a changé ma vie). He had his first leading role in the 2019 film Living 100 MPH (Vivre à 100 milles à l'heure), playing a semi-fictionalized version of filmmaker Louis Bélanger. In 2020, he starred in the film The Marina (La Marina). In 2023, he was announced as playing Gilles Villeneuve in Villeneuve: The Rise of a Legend (Villeneuve : l'ascension d'une légende), which premiered as the closing film of the 2026 Toronto International Film Festival.
== Further reading == Nagano N, Ota M, Nishikawa K (September 1999). "Strong hydrophobic nature of cysteine residues in proteins". FEBS Lett. 458 (1): 69–71. Bibcode:1999FEBSL.458...69N. doi:10.1016/S0014-5793(99)01122-9. PMID 10518936. S2CID 34980474.
Sources: en.wikipedia.org
==== MeSH E05.478.605 – immunoprecipitation ==== MeSH E05.478.605.160 – chromatin immunoprecipitation MeSH E05.478.605.492 – precipitin tests MeSH E05.478.605.492.300 – flocculation tests MeSH E05.478.605.492.350 – immunodiffusion MeSH E05.478.605.492.350.350 – immunoelectrophoresis MeSH E05.478.605.492.350.350.150 – counterimmunoelectrophoresis MeSH E05.478.605.492.350.350.350 – immunoelectrophoresis, two-dimensional MeSH E05.478.605.825 – radioimmunoprecipitation assay
== See also == Ambient ionization Atmospheric pressure chemical ionization Atmospheric pressure photoionization Desorption atmospheric pressure photoionization Desorption electrospray ionization Electric glow discharge
== Related compounds == Numerous other compounds similar to levonantradol were also developed at the same time, including CP 42,096, CP 47,497, CP 55,940 and CP 55,244. The desacetyl derivative of levonantradol (DALN or CP 54,939) and its N-methyl derivative, as well as the tetracyclic analogue all have similar activity to levonantradol itself.
=== Spider and other silks === Spider silk, particularly the dragline silk of orb-weaving spiders, is both very strong and highly extensible, which places it among the toughest natural fibres known. The principal constraint is supply. Spiders are territorial and cannibalistic and cannot be farmed as silkworms are, so natural spider silk remains scarce. Instead, spider-silk proteins are produced by genetic engineering and expressed in bacteria, yeast or other hosts. Silks from wild silkmoths such as Antheraea species, and from other insects, have also been examined; they differ in amino acid sequence and in how they interact with cells.
=== Supercritical desalination === The solubility of dissolved ions drops precipitously once a fluid becomes supercritical. This effect can be used to precipitate salts from high salinity desalination streams, with solubility of different salts decreasing rapidly as water approaches supercritical temperatures. Complex cycle design can enable selective precipitation and improved heat recovery. Some very saline water sources like produced water also have high hydrocarbon content, which can be oxidized by supercritical desalination.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.